Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

NCT02616783 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

167

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: E/C/F/TAF
DRUG: TDF
DRUG: FTC
DRUG: FTC/TDF
DRUG: 3TC
DRUG: Third agent

Sponsor

Gilead Sciences